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Abstract
Background: Numerous cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS), but studies
are often limited to whole blood (WB) or peripheral blood mononuclear cells (PBMCs), thereby omitting important
information about the cellular origin of the cytokines. Knowledge about the relation between blood and
cerebrospinal fluid (CSF) cell expression of cytokines and the cellular source of CSF cytokines is even more scarce.
Methods: We studied gene expression of a broad panel of cytokines in WB from relapsing-remitting multiple
sclerosis (RRMS) patients in remission and healthy controls (HCs). Subsequently we determined the gene expression
of the dysregulated cytokines in isolated PBMC subsets (CD4+, CD8+T-cells, NK-cells, B-cells, monocytes and
dendritic cells) from RRMS patients and HCs and in CSF-cells from RRMS patients in clinical relapse and non-
inflammatory neurological controls (NIND).
Results: RRMS patients had increased expression of IFN-gamma (IFNG), interleukin (IL) 1-beta (IL1B), IL7, IL10, IL12A,
IL15, IL23, IL27, lymphotoxin-alpha (LTA) and lymphotoxin-beta (LTB) in WB. In PBMC subsets the main sources of
pro-inflammatory cytokines were T- and B-cells, whereas monocytes were the most prominent source of
immunoregulatory cytokines. In CSF-cells, RRMS patients had increased expression of IFNG and CD19 and decreased
expression of IL10 and CD14 compared to NINDs. CD19 expression correlated with expression of IFNG, IL7, IL12A,
IL15 and LTA whereas CD14 expression correlated with IL10 expression.
Conclusions: Using a systematic approach, we show that expression of pro-inflammatory cytokines in peripheral
blood primarily originates from T- and B-cells, with an important exception of IFNG which is most strongly
expressed by NK-cells. In CSF-cell studies, B-cells appear to be enriched in RRMS and associated with expression of
pro-inflammatory cytokines; contrarily, monocytes are relatively scarce in CSF from RRMS patients and are
associated with IL10 expression. Thus, our findings suggest a pathogenetic role of B-cells and an immunoregulatory
role of monocytes in RRMS.
Keywords: Relapsing-remitting multiple sclerosis, Immunology, Cytokines, Blood, Cerebrospinal fluid cells, Real-time
PCR
Introduction
Multiple sclerosis (MS) is a chronic, immune-mediated
disease of the central nervous system (CNS). An inter-
play among genetic susceptibility and environmental fac-
tors is implicated in the pathogenesis of MS. In
relapsing-remitting MS (RRMS), disability develops with
relapses. The pathological correlates of clinical relapses
are focal, transient attacks of immune cells on myelin
and axons, resulting in the formation of an MS plaque
[1]. In pathology studies of brain tissue from RRMS
patients, T- and B-cells are seen accumulating in peri-
vascular cuffs near MS plaques and to a lesser extent in
the parenchyma, while monocytes and macrophages are
seen mostly in the lesion parenchyma. In the cerebro-
spinal fluid (CSF) many MS patients show a mild pleocy-
tosis. T-cells are the major cell subset in CSF, and
compared to non-inflammatory neurological disease
(NIND) an increase in B-cells and plasma cells and a
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decrease in monocytes and natural killer (NK) cells is
observed in MS patients [2]. The relation between the
peripheral immune system and CNS inflammation in
RRMS is underscored by the efficacy of treatment with
the monoclonal antibodies natalizumab [3] and rituxi-
mab [4], which exert their effect on peripheral immune
cells, but have a major impact on disease activity, cell
numbers, levels of cytokines and markers of tissue dam-
age in CSF [5-7]. During immune attacks on myelin, per-
ipheral activation and subsequent migration of
autoreactive T-helper type 1 (Th1) and Th17 cells to the
CNS is an essential step [8]. How the T-cells become
activated remains unclear, but antigen-presenting cells
(APCs) located in peripheral lymph nodes [9] and the
subarachnoidal space [10] are likely to be involved.
Gene expression studies of brain tissue, peripheral
blood mononuclear cells (PBMCs) and whole blood
(WB) from MS patients have shown dysregulated
expression of cytokines, chemokines, and transcription
factors related to immune activation [11]. Interferon
(IFN)-gamma, the Th1 signature cytokine, has been impli-
cated in the pathogenesis of MS, and induced disease ac-
tivity in a clinical trial [12], although in the animal model
experimental autoimmune encephalomyelitis (EAE), Ifng
knockout mice developed severe disease [13]. In addition
to Th1-cells, Th17-cells that secrete interleukin (IL)-17
are believed to be important in the pathogenesis [8].
Since gene expression studies of molecules used in
biomarker studies are mostly carried out on WB or
PBMCs, the cellular origin of cytokines is usually not
determined. To date, no study has systematically ana-
lyzed the cellular origin of dysregulated cytokines in MS
patients. Furthermore little is known about cytokine ex-
pression in CSF-cells and the cellular source of CSF
cytokines. CSF studies are sparse due to the limited
availability of CSF, but studies linking peripheral and
CSF immune responses are central to understanding the
immunopathogenesis of MS, and to translate the many
findings in studies of peripheral immune activation.
In the present study, we used gene expression analysis
to identify dysregulated cytokines in WB from RRMS
patients in clinical remission and subsequently investi-
gated the cellular source of these cytokines in isolated
PBMC subsets. Furthermore, to relate the findings in
peripheral blood to CNS inflammation, we studied gene
expression of the dysregulated cytokines in CSF-cells
from RRMS patients in relapse, and determined whether
it correlated with markers for T-, B- and NK-cells and
monocytes in the CSF.
Materials and methods
Subjects
An initial cohort of 39 untreated RRMS patients in clin-
ical remission and 39 healthy controls (HCs) was
recruited for studies of gene expression in WB (Table 1).
A second cohort of four untreated RRMS patients in re-
mission and four HCs was recruited for studies of gene
expression in isolated PBMC subsets. Finally a third co-
hort of 17 untreated RRMS patients in relapse and 10
NIND patients (3 with spinal stenosis, 3 with herniated
lumbar discs and 4 with low back pain) were recruited
for studies on CSF-cells and PBMCs; CSF sampling was
done prior to initiation of eventual steroid pulse therapy.
All RRMS cohorts studied consisted of both recent onset
RRMS and RRMS with longer disease duration (Table 1).
The studies were approved by the local scientific ethics
committee and informed consent was obtained from all
patients and healthy controls.
Gene expression studies
WB was sampled in PAXgene tubes and RNA extracted
using PAXgene Blood RNA Kit (PreAnalytiX, Hom-
brechtikon, Switzerland); cDNA synthesis was done with
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, California, USA). For studies of
gene expression in PBMC subsets, PBMCs were isolated
using Lymphoprep (Axis-Shield, Oslo, Norway) and sub-
sets of CD4+T-cells, CD8+T-cells, NK-cells, B-cells,
monocytes and dendritic cells (DC) were isolated using
MACS cell separation kits (CD4+T Cell Isolation Kit,
CD8+T Cell Isolation Kit, NK Cell Isolation Kit, CD19
MicroBeads, CD14 MicroBeads and Blood Dendritic Cell
Isolation Kit) and an autoMACS separator (all from Mil-
tenyi Biotec, Bergisch Gladbach, Germany). Mean puri-
ties of the PBMC subsets were above 93%, except for
NK-cells which had a mean purity of 73%. RNA was
extracted from 80,000 to 200,000 cells of the obtained
subsets with PicoPure RNA Isolation Kit (Arcturus,
Mountain View, California, USA). cDNA synthesis was
done with qScript cDNA SuperMix (Quanta
Table 1 Demographic and clinical characteristics of the cohorts
RRMS patients Control groups
Median age Female% Median EDSS Duration Mean age Female%
Whole blood studies 34.0 (28.0 to 39.0) 59% 2.0 (1.0 to 3.0) 5.0 (2.0 to 7.0) 32.0 (29.0 to 38.0) 58%
Cell subset studies 38.0 (30.5 to 47.0) 75% 1.5 (1.0 to 3.1) 5.0 (1.3 to 12.5) 33.5 (24.5 to 36.5) 75%
CSF cell studies 37.5 (31.3 to 42.8) 59% 3.5 (3.0 to 6.4) 6.0 (1.5 to 9.75) 51.5 (45.0 to 59.0) 70%
Median values with interquartile ranges in brackets. EDSS, Expanded Disability Status Scale; RRMS, relapsing-remitting multiple sclerosis.
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BioSciences, Gaithersburg, Maryland, USA). For CSF-
cell gene expression studies, CSF was obtained by lum-
bar puncture within 30 days from the onset of a relapse
with no evidence of spontaneous recovery. Blood was
sampled on the same day as the lumbar puncture and
PBMCs were isolated with Lymphoprep. We snap froze
at least 5,000 CSF-cells and 200,000 PBMCs for later
RNA extraction with PicoPure RNA Isolation Kit and
cDNA synthesis with High Capacity cDNA Reverse
Transcription Kit.
In the selection of the genes of interest (Table 2), we
focused on genes that have been shown to be involved
in the pathogenesis of MS, genes involved in the expres-
sion of Th1 and Th17 cytokines, and genes expressed in
APCs. In a pilot study in the WB cohort we excluded
IL1A, IL2, IL4, IL5, IL6, IL9, IL12B, IL13, IL17A, IL17F,
IL21, IL33, GM-CSF and BDNF from analysis as candi-
date biomarkers due to low expression levels in WB
samples. Real-time polymerase chain reactions (RT-PCR)
were performed with TaqMan Gene Expression Assays
on a 7500 Real-Time PCR System (Applied Biosystems,
USA). Threshold cycle (CT) values were calculated using
SDS software (Applied Biosystems, USA). In CSF-cell
samples without amplification the expression value was
arbitrarily set to 0. The relative mRNA transcript
expression was calculated by the comparative CT
method also referred to as the 2-ΔΔCT method, using
GAPDH as reference gene. Expression values were nor-
malized to a HC PBMC cDNA pool resulting in a
normalization ratio (NR):
NR ¼ 2ΔΔCT ;
where
ΔΔCT ¼ CTtarget=sample  CTtarget=pool
 
 CTGAPDH=sample  CTGAPDH=pool
 
Statistical analysis
Statistical analysis was performed using PASW 18 soft-
ware (IBM, Armonk, New York, USA). For comparison
between independent groups, non-parametric Mann–
Whitney tests were used. Wilcoxon signed rank tests were
used for analysis of paired samples. For correlation ana-
lysis, we used Spearman's rank correlation coefficient.
Changes in the expression of mRNA were considered sig-
nificant for P <0.05. Since the analysis of gene expression
data involved multiple comparisons, we also used the
false discovery rate (FDR) method to calculate q-values
[14]. Q-values were considered significant for q <0.05.
Table 2 List of TaqMan Gene Expression Assays used in the gene expression studies
Gene Symbol Assay number GenBank Whole blood PBMC populations CSF cells
GAPDH Hs99999905_m1 NM_002046 • • •
IFNG Hs99999041_m1 NM_000619 • • •
IL1B Hs00174097_m1 NM_000576 • • •
IL1RN Hs00277299_m1 NM_000577 •
IL7 Hs00174202_m1 NM_000880 • • •
IL10 Hs00174086_m1 NM_000572 • •
IL12A Hs00168405_m1 NM_000882 • • •
IL15 Hs00542571_m1 NM_172175 • • •
IL18 Hs00155517_m1 NM_001562 •
IL23 Hs00372324_m1 NM_016584 • •
IL27 Hs00377366_m1 NM_145659 • • •
EBI3 Hs00194957_m1 NM_005755 •
LTA Hs00236874_m1 NM_000595 • • •
LTB Hs00242739_m1 NM_009588 • • •
TGFB1 Hs99999918_m1 NM_000660 •
TNF Hs00174128_m1 NM_000594 •
PRF1 Hs00169473_m1 NM_005041 •
CD3d Hs00174158_m1 NM_000732 • •
CD14 Hs00169122_g1 NM_000591 • •
CD19 Hs01047407_m1 NM_001770 • •
CD56 Hs00941824_m1 NM_181351 • •
Assay numbers listed represents TaqMan Gene Expression Assays used. CSF, cerebrospinal fluid; GenBank, GenBank accession numbers; PBMC, peripheral blood
mononuclear cell.
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Figure 1 (See legend on next page.)
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Results
Gene expression in whole blood from RRMS patients in
remission
Initially, we compared the WB expression of cytokine
genes in RRMS patients in remission and HCs. We
found significantly increased expression of IFN-gamma
(IFNG), IL1B, IL7, IL12A, IL15, IL27, lymphotoxin-alpha
(LTA) and lymphotoxin-beta (LTB) in RRMS (Figure 1).
In previous studies conducted in the same cohort we
found increased expression of IL10 and IL23 [15].
Gene expression in PBMC cell subpopulations from RRMS
patients in remission
To substantiate the findings of increased cytokine gene
expression in WB from RRMS patients in remission, we
conducted gene expression studies on PBMC subsets
from four RRMS patients in remission and four HCs.
Due to the low number of subjects, we did not expect to
find differences between the two groups. As shown in
Figure 2, the cellular sources of IFNG are mainly NK-
cells, CD8+T-cells and, to a lesser extent, CD4+T-cells.
This is not unexpected, but highlights NK-cells as a
major source of IFNG and thus questions the use of
IFNG as a specific Th1 biomarker in peripheral blood
studies without detailing the cellular source. For IL1B,
the cellular sources are mainly monocytes and DCs.
Notably, IL1B expression in WB is higher than in
PBMCs, reflecting that granulocytes are a major source
of IL1B in WB. IL10 is expressed in monocytes, CD4+
and CD8+T-cells. IL7 and IL12A are expressed mainly in
B-cells and IL15 mainly in B-cells and monocytes. For
IL23, the cellular sources are CD4+T-cells, CD8+T-cells
and B-cells. Unexpectedly, we observed low expression
in monocytes and DCs. This finding contradicts the
current understanding of IL23, which is thought to be
an APC cytokine. However, since IL23A transcripts are
translated into IL23p19 protein, which together with
IL12p40 form bioactive IL23, and IL12p40 production is
known to be limited to activated monocytes and DCs
[16] and B-cells [17], the biological role of IL23 expres-
sion in T-cells is unclear. Thus, our findings indicate
that in vivo WB IL23 gene expression is not suitable for
studying IL23, which should instead be studied at the
protein level as IL-23 p19/IL-12 p40 heterodimer. IL27
expression is restricted to monocytes. LTA is mainly
expressed in CD4+T-cells, CD8+T-cells and B-cells and,
to a lesser extent, in NK-cells while LTB is mainly
expressed in B-cells, CD4+T-cells and at lower levels in
CD8+T-cells.
Gene expression in PBMCs and CSF-cells from RRMS
relapse patients
Next, we wanted to relate the findings of dysregulated
cytokines in peripheral blood cells with CNS inflamma-
tion. We analyzed the cytokine expression in CSF-cells
and PBMCs from a cohort of RRMS relapsed and NIND
patients (Table 3). IL10 expression was significantly
enriched in CSF-cells compared to PBMCs with a 9-fold
increase in RRMS relapse patients and a 42-fold increase
in NINDs. LTB expression was higher in CSF-cells than
in PBMCs with a 2.4-fold increase in RRMS relapsed
patients and a 1.7-fold increase in NINDs. IL1B expres-
sion in CSF-cells was 0.18-fold lower than in PBMCs in
RRMS relapsed patients. Compared with NIND, RRMS
patients had increased IFNG and decreased IL10 expres-
sion in CSF-cells. The IFNG and LTA CSF/PBMC ratios
were significantly higher in RRMS relapsed patients,
while the IL10 CSF/PBMC ratio was lower in RRMS
than in NIND patients. In CSF-cells IL7 and IL15 ex-
pression was only detectable in a few samples (all from
RRMS patients).
CSF-cell subsets and cytokine gene expression in RRMS
relapse patients
To elucidate whether differences in cytokine gene ex-
pression are associated with the cell subsets present in
CSF, we analysed gene expression of CD3d, CD14, CD19
and CD56 (markers of T-cells, monocytes, B-cells and
NK-cells and NK T-cells, respectively) in CSF-cells
(Table 4). Comparing expression of cell type markers in
CSF-cells to PBMCs, we found significantly increased
expression of CD3d in CSF-cells in RRMS relapse
patients and increased CD14 expression in CSF-cells
from NINDs. RRMS relapse patients had a decrease in
the expression of CD14 and the CD14 CSF/PBMC ratio
and an increase in expression of CD19 and the CD19
CSF/PBMC ratio compared with NIND patients.
Correlations between CSF cytokine expression and cell
type markers were analyzed using Spearman’s rank cor-
relation analysis. Since several of the gene targets were
only expressed in some patients, resulting in low statis-
tical power, we analyzed correlations for the whole co-
hort and for the cohort of RRMS patients in relapse
(Table 5). For the whole cohort, INFG and CD19
(See figure on previous page.)
Figure 1 Cytokine gene expression in whole blood from multiple sclerosis patients and healthy controls. Whole blood gene expression
data from relapsing-remitting multiple sclerosis (RRMS) patients in remission and healthy controls are shown as the normalization ratio (NR).
Mann–Whitney tests were used for testing differences between groups, and q-values represent false discovery rate corrected P-values. Significant
test-values are in bold.






















































































































































































































































Figure 2 (See legend on next page.)
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expression correlated positively, and INFG and CD14 ex-
pression correlated negatively. IL10 expression corre-
lated positively with CD14 and negatively with CD19.
IL10 expression in CSF-cells correlated significantly with
CD14 expression, suggesting that monocytes are an
important source of IL10 in CSF-cells. Consistent with
the PBMC subset findings, we further found positive
correlations between CD19 and IFNG, IL7, IL12A, IL15
and LTA; CD3d and LTB; CD56 and IL12A. These find-
ings also reached statistical significance when FDR-
(See figure on previous page.)
Figure 2 Sources of cytokines in peripheral blood cell subsets. Box-plots of cytokine gene expression for different cell populations are
isolated from relapsing-remitting patients in remission (RRMS rem) and healthy controls (HC). Gene expression data are shown as the
normalization ratio (NR)
Table 3 Cytokine expression in cerebrospinal fluid cells and peripheral blood mononuclear cells
RRMS relapse NIND RRMS relapse vs NIND
Mean CT
value
N Median (IQR) CSF/PBMC
p-value
N Median (IQR) CSF/PBMC
p-value
p-value q-value
IFNG PBMC NR 32.3 15 4.10 (2.74 to 10.21) 10 5.25 (2.65 to 9.12) 0.78 0.37
IFNG CSF NR 34.9 15 7.22 (0.00 to 16.42) 10 0.00 (0.00 to 0.00) 0.004 0.02
IFNG CSF/PBMC Ratio 15 0.71 (0.00 to 2.31) 0.87 10 0.00 (0.00 to 0.00) 0.004 0.02
IL1B PBMC NR 32.4 16 1.13 (0.88 to 2.14) 10 1.81 (1.05 to 2.70) 0.19 0.15
IL1B CSF NR 36.7 14 0.21 (0.00 to 1.09) 10 2.70 (0.00 to 6.94) 0.36 0.23
IL1B CSF/PBMC Ratio 13 0.18 (0.00 to 0.92) 0.02 10 1.96 (0.00 to 6.40) 0.29 0.42 0.24
IL7 PBMC NR 34.0 16 0.41 (0.21 to 1.17) 10 0.31 (0.18 to 0.46) 0.40 0.24
IL7 CSF NR 36.1 13 0.00 (0.00 to 0.86) 10 0.00 (0.00 to 0.00) 0.06 0.09
IL7 CSF/PBMC Ratio 12 0.00 (0.00 to 2.51) 8 0.00 (0.00-0.00) 0.08 0.09
IL10 PBMC NR 34.3 16 2.75 (2.02 to 3.90) 10 2.95 (2.38 to 4.26) 0.54 0.27
IL10 CSF NR 35.3 17 23.51 (3.22 to 46.39) 10 116.78 (72.22 to 156.28) 0.001 0.01
IL10 CSF/PBMC Ratio 16 8.57 (0.79 to 12.71) 0.003 10 42.21 (24.04 to 66.18) 0.01 0.002 0.01
IL12A PBMC NR 37.5 16 0.49 (0.30 to 0.66) 10 0.54 (0.42 to 0.82) 0.53 0.27
IL12A CSF NR 38.3 15 0.00 (0.00 to 0.00) 10 0.00 (0.00 to 0.00) 0.24 0.17
IL12A CSF/PBMC Ratio 12 0.00 (0.00 to 0.00) 9 0.00 (0.00 to 0.00) 0.21 0.16
IL15 PBMC NR 36.3 16 1.19 (0.91 to 1.43) 10 1.10 (0.57 to 1.60) 0.79 0.37
IL15 CSF NR 37.3 14 0.00 (0.00 to 1.10) 10 0.00 (0.00 to 0.00) 0.07 0.09
IL15 CSF/PBMC Ratio 13 0.00 (0.00 to 0.97) 10 0.00 (0.00 to 0.00) 0.06 0.09
IL23 PBMC NR 34.6 16 0.80 (0.65 to 1.18) 10 0.80 (0.62 to 1.15) 1.00 0.44
IL23 CSF NR 36.8 14 1.12 (0.00 to 1.98) 10 0.00 (0.00 to 0.48) 0.10 0.10
IL23 CSF/PBMC Ratio 13 1.54 (0.00 to 3.17) 0.28 10 0.00 (0.00 to 1.50) 0.09 0.10
IL27 PBMC NR 35.1 16 4.74 (2.49 to 7.60) 10 8.36 (6.17 to 12.70) 0.045 0.09
IL27 CSF NR ND 14 0.00 (0.00 to 0.00) 10 0.00 (0.00 to 0.00) 1.00 0.44
IL27 CSF/PBMC Ratio 12 0.00 (0.00 to 0.00) 10 0.00 (0.00 to 0.00) 1.00 0.44
LTA PBMC NR 34.3 16 1.74 (1.43 to 2.30) 10 2.11 (1.59 to 2.73) 0.37 0.23
LTA CSF NR 36.7 14 1.41 (0.00 to 3.20) 10 0.00 (0.00 to 0.00) 0.05 0.09
LTA CSF/PBMC Ratio 13 1.08 (0.00 to 1.82) 0.92 10 0.00 (0.00 to 0.00) 0.04 0.09
LTB PBMC NR 28.2 16 4.09 (2.44 to 4.99) 10 3.71 (3.06 to 5.54) 0.79 0.37
LTB CSF NR 33.5 13 8.05 (6.62 to 13.37) 10 8.82 (3.30 to 12.27) 0.42 0.23
LTB CSF/PBMC Ratio 12 2.37 (1.76 to 3.12) 0.002 10 1.70 (0.97 to 3.12) 0.04 0.13 0.11
Gene expression data are shown as the normalization ratio (NR). Mean cycle threshold (CT) is shown for each target. CSF/PBMC ratio represent fold change in
expression between CSF cells and PBMCs. CSF/PBMC P-values represents Wilcoxon signed rank test results, and tests were only conducted if median CSF NR was
>0. All other P-values represent Mann–Whitney tests for differences between groups, and q-values represent false discovery rate corrected P-values. Significant
test-values are in bold. CSF, cerebrospinal fluid; IQR, Interquartile range; NIND, non-inflammatory neurological disease; PBMC; peripheral blood mononuclear cell;
RRMS relapse, relapsing-remitting multiple sclerosis patients in relapse.
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corrected q-values were calculated. For RRMS relapse
patients some of the correlations were confirmed, but
none of them reached statistical significance when q-
values were calculated.
Discussion
In the present study we find an increased expression of
pro-inflammatory (INFG, IL1B, IL7, IL12A, IL15, IL23,
LTA and LTB) and immunoregulatory cytokines (IL10
and IL27) in WB from RRMS patients in remission. In
subsequent gene expression studies on PBMC subsets,
our findings confirm the expected sources for many
cytokines, but for others we reveal unexpected cell-types
to be major sources. In general, T- and B-cells are the
most frequent sources of the pro-inflammatory cyto-
kines, and monocytes are the predominant source of the
immunoregulatory cytokines. In CSF-cell studies, we
demonstrate that the majority of the cytokines are
expressed by CSF-cells, and that CSF-cells from RRMS
patients have increased expression of IFNG and markers
of T- and B-cells, whereas IL10 and the marker for
monocytes have decreased expression. Finally, the B-cell
marker CD19 correlated positively with many pro-
inflammatory cytokines in CSF-cells.
We present a systematic approach to determine the
cellular source of dysregulated cytokines in RRMS,
which is critical in the interpretation of findings in cyto-
kine biology. Our studies addressed the expression of
genes that may serve as biomarkers of fundamental
pathogenic processes in MS in fresh blood samples,
which allows studying cytokine biology close to in vivo
conditions, without the need for in vitro stimulation.
However, in vivo studies have limitations, since they do
not address the full potential for activation of the cells in
the same way that in vitro studies do. Furthermore, gene
expression does not necessarily result in translation into
bioactive protein, and post-translational modifications or
regulated secretion are not reflected by mRNA expres-
sion studies. The studies on isolated cell-subsets were
generally performed on samples with high purity, but for
NK-cells the purity was 73% on average. This could rep-
resent a potential bias, as genes not normally detected in
NK-cells possibly will be detected. Thus, for genes with
low expression levels in NK-cells, conclusions must be
very cautious. On the other hand, the very high expres-
sion of IFNG by NK-cells is not likely to be a result of
this impurity. The CSF-cell study had limited statistical
power due to the relatively low number of subjects and
the low amount of mRNA that could be extracted from
these cells. This implies that more target molecules
might have been detected if more mRNA had been avail-
able. Caution is therefore important in the interpretation
of differences in expression levels between PBMCs and
CSF-cells in MS patients and controls. Not only will dif-
ferences in the cellular composition of CSF samples in
MS patients and neurological controls confound the
results obtained, but differences in the composition of
blood and CSF-cell populations common to patients and
controls should also be taken into account. Adding to
this, specific cell-subsets might change their phenotype or
gene expression patterns upon crossing the blood–brain-
barrier [18,19].
Table 4 Expression of markers of cell types in cerebrospinal fluid cells and peripheral blood mononuclear cells
RRMS relapse NIND RRMS relapse vs NIND
Mean CT N Median (IQR) CSF/PBMC
p-value
N Median (IQR) CSF/PBMC
p-value
p-value q-value
CD3d PBMC NR 31.1 15 0.06 (0.04 to 0.08) 10 0.05 (0.04 to 0.07) 0.47 0.26
CD3d CSF NR 35.6 13 0.10 (0.08 to 0.23) 10 0.06 (0.02 to 0.15) 0.07 0.09
CD3d CSF/PBMC Ratio 11 2.37 (1.30 to 3.67) 0.01 10 1.12 (0.42 to 3.07) 0.39 0.23 0.17
CD14 PBMC NR 30.1 15 0.33 (0.27 to 0.38) 10 0.33 (0.29 to 0.49) 0.38 0.23
CD14 CSF NR 34.9 13 0.38 (0.07 to 0.52) 10 1.52 (0.94 to 2.40) 0.0004 0.01
CD14 CSF/PBMC Ratio 11 1.39 (0.30 to 2.15) 0.42 10 4.01 (3.54 to 5.16) 0.01 0.003 0.02
CD19 PBMC NR 36.1 15 0.14 (0.09 to 0.23) 10 0.08 (0.05 to 0.16) 0.05 0.09
CD19 CSF NR 37.1 13 0.00 (0.00 to 0.35) 10 0.00 (0.00 to 0.00) 0.03 0.09
CD19 CSF/PBMC Ratio 11 0.00 (0.00 to 0.89) 10 0.00 (0.00 to 0.00) 0.04 0.09
CD56 PBMC NR 34.9 15 0.15 (0.09 to 0.23) 10 0.16 (0.07 to 0.32) 0.96 0.43
CD56 CSF NR 37.8 13 0.00 (0.00 to 0.03) 10 0.00 (0.00 to 0.00) 0.11 0.10
CD56 CSF/PBMC Ratio 11 0.00 (0.00 to 0.00) 10 0.00 (0.00 to 0.00) 0.17 0.14
Gene expression data are shown as normalization ratio (NR). Mean cycle threshold (CT) is shown for each target. CSF/PBMC ratio represent fold change in
expression between CSF cells and PBMCs. CSF/PBMC p-values represents Wilcoxon signed rank test results, and tests were only conducted if median CSF NR was
>0. All other p-values represent Mann–Whitney tests for difference between groups, and q-values represent false discovery rate corrected p-values. Significant
test-values are in bold. RRMS relapse: Relapsing-remitting multiple sclerosis patients in relapse. NIND: Non-inflammatory neurological disease. PBMC: Peripheral
blood mononuclear cell. CSF: Cerebrospinal fluid. IQR: Interquartile range.
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Looking into the possible roles of specific cytokines
found to be dysregulated in our patients with RRMS,
IFN-gamma is known to be present in brain lesions in
MS patients [20], and IFN-gamma secretion is increased
in T-cells from RRMS patients in the blood and even
more in CSF. Experimental studies indicate that IFN-
gamma, at least when expressed by CD4+T-cells, has im-
portant effects along with IL17 in the development of
RRMS [8]. Our findings of increased IFNG in WB and
CSF-cells in RRMS patients are in accordance with
Table 5 Correlations between cytokine and cell type marker expression in cerebrospinal fluid cells
RRMS relapse and NIND RRMS relapse
CSF NR N R p-value q-value N R p-value q-value
IFNG vs CD3d 22 0.383 0.08 0.06 12 0.441 0.151 0.39
IFNG vs CD14 22 −0.606 0.003 0.008 12 0.018 0.956 0.90
IFNG vs CD19 22 0.538 0.010 0.02 12 0.111 0.731 1.04
IFNG vs CD56 22 0.372 0.09 0.06 12 0.019 0.954 0.93
IL1B vs CD3d 23 −0.453 0.03 0.03 13 0.064 0.837 0.89
IL1B vs CD14 23 0.126 0.57 0.27 13 0.067 0.829 0.91
IL1B vs CD19 23 0.168 0.44 0.21 13 0.435 0.137 0.39
IL1B vs CD56 23 0.110 0.62 0.28 13 0.285 0.345 0.73
IL7 vs CD3d 23 0.090 0.68 0.30 13 −0.121 0.694 1.03
IL7 vs CD14 23 −0.169 0.44 0.22 13 0.087 0.777 0.98
IL7 vs CD19 23 0.600 0.002 0.009 13 0.513 0.073 0.36
IL7 vs CD56 23 0.412 0.05 0.04 13 0.241 0.429 0.86
IL10 vs CD3d 23 −0.506 0.01 0.02 13 −0.589 0.034 0.23
IL10 vs CD14 23 0.773 0.00002 0.00011 13 0.541 0.056 0.32
IL10 vs CD19 23 −0.438 0.04 0.04 13 −0.151 0.623 1.01
IL10 vs CD56 23 −0.242 0.27 0.15 13 0.086 0.781 0.95
IL12A vs CD3d 23 0.075 0.73 0.31 13 −0.096 0.755 1.03
IL12A vs CD14 23 −0.327 0.13 0.08 13 −0.236 0.437 0.78
IL12A vs CD19 23 0.577 0.004 0.008 13 0.508 0.076 0.32
IL12A vs CD56 23 0.756 0.00003 0.00014 13 0.697 0.008 0.09
IL15 vs CD3d 23 0.226 0.30 0.16 13 0.067 0.828 0.94
IL15 vs CD14 23 −0.519 0.01 0.02 13 −0.450 0.123 0.42
IL15 vs CD19 23 0.847 0.0000003 0.0000048 13 0.758 0.003 0.09
IL15 vs CD56 23 0.469 0.02 0.03 13 0.349 0.242 0.59
IL23 vs CD3d 23 0.004 0.98 0.39 13 0.034 0.912 0.91
IL23 vs CD14 23 −0.396 0.06 0.05 13 −0.040 0.898 0.92
IL23 vs CD19 23 0.340 0.11 0.07 13 0.177 0.562 0.96
IL23 vs CD56 23 0.234 0.28 0.15 13 0.092 0.766 1.00
LTA vs CD3d 23 0.002 0.99 0.39 13 −0.121 0.693 1.07
LTA vs CD14 23 −0.420 0.05 0.04 13 −0.078 0.800 0.94
LTA vs CD19 23 0.563 0.005 0.009 13 0.461 0.113 0.43
LTA vs CD56 23 0.384 0.07 0.05 13 0.238 0.433 0.82
LTB vs CD3d 23 0.579 0.004 0.009 13 0.440 0.133 0.41
LTB vs CD14 23 −0.057 0.80 0.33 13 0.305 0.310 0.70
LTB vs CD19 23 −0.337 0.12 0.07 13 −0.702 0.008 0.13
LTB vs CD56 23 −0.304 0.16 0.09 13 −0.598 0.031 0.26
Gene expression data are shown as the normalization ratio (NR). Correlation analysis was done with Spearman’s rank correlation coefficient, and q-values
represent the false discovery rate corrected P-values. Significant values are in bold. RRMS relapse: Relapsing-remitting multiple sclerosis patients in relapse. CSF
cerebrospinal fluid; NIND, Non-inflammatory neurological disease; PBMC, Peripheral blood mononuclear cell.
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previous studies, but the finding of NK-cells and CD8+T-
cells as the major sources highlights that IFNG expression
in WB is associated with other cellular responses than
Th1. As NK-cells have been attributed an immunoregula-
tory role in MS, this could explain the known ambiguous
effects of IFN-gamma in MS and animal models of MS,
and our finding emphasizes that further clarification of
the function of IFN-gamma in MS requires studies of
NK-cells and CD8+T-cells. The finding of increased IFNG
expression in CSF-cells is more likely attributed a pro-
inflammatory role in T-cells, and interestingly correlates
with B-cells.
We have previously demonstrated negative correlation
between expression of the immunoregulatory cytokine
IL10 and the number of active magnetic resonance im-
aging lesions [21], and IL10 has been suggested to have
beneficial effects in MS in numerous studies [22,23].
IL10 is present in perivascular macrophages in MS
lesions [24] and is increased in CSF from MS patients
[25]. In blood, studies of IL10 expression have been con-
flicting [25-27] but most biomarker studies point to a
slight increase in IL10 gene expression in MS. Accord-
ingly, we find IL10 expression to be increased in WB
from RRMS in remission compared to HCs. In CSF-cells
we find a decrease in IL10 mRNA expression in RRMS
relapse compared to NIND patients. This corresponds
to a study showing that IL10-protein is decreased during
relapses [28], whereas data from a study on a mixed MS
group and a non-inflammatory control group [29],
reported increased IL10 mRNA expression in in CSF-
cells from MS. The latter study used a mixed MS group
where the majority was not in relapse, and hence a likely
explanation for the conflicting results is the differences
in the specific patient groups studied. Finally, since IL10
expression was pronounced in monocytes in our PBMC
subset study and correlated negatively with CD3d and
CD19 and positively with CD14 in CSF-cells, our find-
ings support that monocytes may have an immunoregu-
latory role in MS. However, the decreased CSF-cell IL10
expression in RRMS compared to NIND patients could
also simply reflect a relatively decreased frequency of
monocytes in MS patients [2] or a change in the mono-
cyte phenotype, since monocytes transmigrating across
the blood–brain barrier change their phenotype [19],
and CSF monocytes have decreased CD14 expression
[18,30].
IL7 and IL15 are IL-2 family cytokines regulating sur-
vival and activation of lymphocytes, and are of interest
in MS research since they signal through the IL2- and
IL7-receptors, which have shown strong association with
MS in genome-wide association studies [31]. Expression
of these cytokines is increased in MS brain lesions
[32,33], in CSF [34,35] and in blood from MS patients
[36,37]. The finding of increased WB expression is in
accordance with previous studies on blood cells. Since
IL7 and IL15 both contribute to increased T-cell survival
and Th1 induction, our findings could represent a B-cell
and monocyte-driven pro-inflammatory response in the
peripheral immune compartment of MS patients. On
the other hand IL15 is also essential for NK-cell survival
and IL15-deficiency in mice results in worsening of EAE
[38], why caution in the interpretation of the IL15 find-
ings should be stressed.
The finding of IL23 expression being most pro-
nounced in T-and B-cells, make clear that a systematic
approach can be necessary to derive proper conclusions
about the biology behind cytokine gene expression, and
in this particular example, that the biological significance
of in vivo IL23 expression is unclear and will demand
studies of IL23 expression in T-cells.
Lymphotoxin is present in MS lesions [39] and expres-
sion is increased in blood and CSF in MS [40,41]. Being
important for the crosstalk between APCs and T-cells
and for the development of ectopic follicle-like struc-
tures seen in MS and other autoimmune diseases [42,43]
our finding of increased lymphotoxin in WB and CSF-
cells points to a probable pro-inflammatory function of
this cytokine in MS, although studies proving that the
increased mRNA expression is associated with increased
bioactivity are needed to substantiate this hypothesis.
Conclusion
In conclusion, we have confirmed previous findings of
dysregulated cytokines in WB in MS patients, particu-
larly increased expression of pro-inflammatory cyto-
kines. A detailed analysis of the cytokine expression in
PBMC subsets confirmed the expected origin for some
cytokines, while other cytokines also were expressed in
unexpected subsets. Most pro-inflammatory cytokines
were expressed by B-cells in blood and correlated with
CD19 in CSF-cells. Monocytes were the predominant
source of immunoregulatory cytokines, and IL10 was
decreased in CSF-cells compared to NINDs, and corre-
lated with CD14 in CSF-cells. These findings correspond
to studies on CSF-cells in MS [44,45] and a study show-
ing that the most variable cell parameter in CSF is the
B-cell/monocyte ratio, which also correlates with disease
progression [2]. Thus our study supports a central role
of B-cells in the pathogenesis of MS. Recently this has
been highlighted by studies proving the benefit of treat-
ment with B cell-depleting antibodies in MS [46].
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